There were significant prognostic differences in 4 glioma subgroups (GBM IDH wildtype, GBM IDH mutant, Oligodendroglioma II-III, Astrocytoma II-III) (Figure 7). This evidence concerns the gene IDH1 and oligodendroglioma.